Invenra is pleased to announce and welcome back, Mark F. Kubik as Chief Business Officer. Mark will lead the Invenra business development team, developing and managing new business opportunities in addition to leadership of alliance and portfolio management, and overseeing its pipeline of immuno-oncology bispecific (B-Body™) antibodies and strategic partnerships.
Mr. Kubik has over 25 years of experience in business development, alliance and portfolio management and drug discovery and development. The bulk of this work has focused around successfully leading transformative deal creation and productive alliances in the therapeutic monoclonal antibody (mAb) and empowered antibody areas. Previously, Mark had led Invenra’s early business development efforts as SVP, Business Development and was responsible for several important mAb discovery partnerships and strategic guidance. Mark’s leadership also directed Invenra toward its current strategic focus on multispecific mAbs in Immuno-Oncology for its own pipeline and for strategic partners.
Read more at BusinessWire.